Skip to main content Accessibility help
×
Home

Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity

  • Stephen M. Stahl (a1)

Abstract

Although currently available antidepressants increase monoamine levels soon after the start of treatment, therapeutic benefits are often delayed by several weeks and the majority of patients with major depressive disorder fail to achieve an adequate response to first- or second-line therapies targeting monoamines. The recent approval of the NMDA (N-methyl-d-aspartate) antagonist esketamine given intranasally for treatment-resistant depression has reinforced the need for agents with rapid onset with alternate mechanisms of action. Dextromethorphan/bupropion, an investigational medicine currently in development, is one such candidate.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity
      Available formats
      ×

Copyright

References

Hide All
1.Stahl, SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. New York, NY: Cambridge University Press; 2013.
2.NUEDEXTA® Prescribing Information. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; January 2019.
3.WELLBUTRIN® Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; August 2017.
4.O’Gorman, C, Iosifescu, DV, Jones, A, et al. Clinical development of AXS-05 for treatment resistant depression and agitation associated with Alzheimer’s disease. P7122. Presented at the APA Annual Meeting 2018; May 5-9, 2018; New York, NY.
5.Crupi, R, Marino, A, and Cuzzocrea, S. New Therapeutic Strategy for Mood Disorders. Curr Med Chem. 2011; 18(28):4284–98.
6.Sen, S, Duman, R, and Sanacora, G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol Psychiatry 2008; 64:527532.
7.Deyama, S, Bang, E, Wohleb, ES, et al. Role of neuronal VEGF signaling in the prefrontal cortex in the rapid antidepressant effects of ketamine. Am J Psychiatry. 2019;176:388400.
8.Niciu, MJ, Ionescu, DF, Richards, EM, Zarate, CA. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna). 2014;121(8):907924.
9.Freudenberg, F, Celikel, T, Reif, A. The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity? Neurosci Biobehav Rev. 2015;52:193206.
10.Zarate, C, Machado-Vieira, R, Henter, I, et al. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry. 2010;18(5):293303.
11.Nguyen, L, Matsumoto, RR. Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. Behav Brain Res. 2015;295:2634.
12.Berman, FW, Murray, TF. Characterization of [3H]MK-801 binding to N-methyl-D-aspartate receptors in cultured rat cerebellar granule neurons and involvement in glutamate-mediated toxicity. J Biochem Toxicol. 1996;11(5):217226.
13.Werling, LL, Keller, A, Frank, JG, Nuwayhid, SJ. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007;207(2):248257.
14.Robson, MJ, Elliott, M, Seminerio, MJ, Matsumoto, RR. Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol. 2012;22(4):308317.
15.Lauterbach, EC. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med Hypotheses. 2012;78(6):693702.
16.Williams, NR, Heiferts, BD, Blasey, C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175(12):12051215.
17.Wang, M and Kaplin, A. Explaining naltrexone’s interference with ketamine’s antidepressant effect. Am J Psychiatry. 2019;176(5):410–11.
18.Heiferts, BD, Williams, NR, Blasey, C, et al. Rigorous translational models are key to studying ketamine’s antidepressant mechanism: Response to Wang and Kaplin. Am J Psychiatry. 2019;176(5):412.
19.Gaginella, TS, Bertko, RJ, Kachur, JF. Effect of dextromethorphan and levomethorphan on gastric emptying and intestinal transit in the rat. J Pharmacol Exp Ther. 1987;240(2):388391.
20.Kachur, JF, Morgan, DW, Gaginella, TS. Effect of dextromethorphan on guinea pig ileal contractility in vitro: comparison with levomethorphan, loperamide, and codeine. J Pharmacol Exp Ther. 1986;239(3):661667.
21.National Institute of Mental Health. Major depression. NIMH website. https://www.nimh.nih.gov/health/statistics/major-depression.shtml. Updated February 2019. Accessed May 19, 2019.
22.World Health Organization. Fact sheets: depression. WHO website. https://www.who.int/news-room/fact-sheets/detail/depression Published March 22, 2018. Accessed May 19, 2019.
23.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):19051917.
24.Nierenberg, AA, Husain, MM, Trivedi, MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010;40(1):4150.
25.McClintock, SM, Husain, MM, Wisniewski, SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31(2):180186.
26.SYMBYAX® Prescribing Information. Indianapolis, IN: Lilly USA, LLC; March 2018.
27.SPRAVATO™ Prescribing information. Titusville, NJ: Janssen Pharmaceuticals; May 2019.
28.ABILIFY® Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd; February 2018.
29.REXULTI® Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd; February 2018.
30.Blier, P, Ward, HE, Tremblay, P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281288.
31.Anderson, A, Iosifescu, DV, Jacobson, M, et al. Efficacy and safety of AXS-05, an oral NMDA receptor antagonist with multimodal activity, in major depressive disorder: results of a phase 2, double-blind, active-controlled trial. W43. Presented at the ASCP Annual Meeting 2019; May 28-31, 2019; Scottsdale, AZ.

Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity

  • Stephen M. Stahl (a1)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

This addendum applies to the following article(s):